ACPU
IDIX

Arrowgrass Capital Partners (US)’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-800,400
Closed -$3.7M – 235
2013
Q3 		$4.15M Buy
+800,400
New +$3.51M 0.16% 111

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s IDIX Position: Q4 2013 in Review

Arrowgrass Capital Partners (US) sold out of IDENIX PHARMACEUTICALS INC (IDIX) in Q4 2013, closing a stake of 800,400 shares — an estimated $3.7M sold.

Arrowgrass Capital Partners (US) first reported a position in IDIX in Q3 2013 and held it in 1 quarter. The position peaked at $4.15M in Q3 2013. 88 funds tracked by Wall St. Rank hold IDIX as of Q4 2013.

  • Arrowgrass Capital Partners (US) reported no remaining IDENIX PHARMACEUTICALS INC position as of Q4 2013 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 800,400 IDENIX PHARMACEUTICALS INC shares in Q4 2013, an estimated $3.7M.
  • Arrowgrass Capital Partners (US) first reported a position in IDENIX PHARMACEUTICALS INC in Q3 2013 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s IDENIX PHARMACEUTICALS INC position peaked at $4.15M in Q3 2013.
  • 88 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q4 2013.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2013, filed 14 Feb 2014.